BB Biotech AG / Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Details of the person subject to the disclosure requirement | |
Name: | Strein, Klaus |
Professional role: | Person with executive functions: Â Member of administrative or supervisory body |
 |  |
Designation of the financial instrument | |
ISIN: | CH0038389992 |
Designation: | Registered share BB Biotech AG |
 |  |
Details of the transaction | |
Type of transaction: | Buy |
Date: | 04.02.2016 |
Place (stock exchange): | Swiss Stock Exchange |
Price: | 229.463 |
Currency: | CHF |
Quantity: | 2600 |
Business volume: | 596603.80 |
 |  |
Details of the company with the publishing obligation: | |
Issuer: | |
BB Biotech AG | |
Schwertstrasse 6 | |
CH-8200 Â Schaffhausen | |
Switzerland |
ISIN: | CH0038389992 |
WKN: | 888509 |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB Biotech AG via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB Biotech AG via Globenewswire
HUG#1984183
--- End of Message ---
BB Biotech AG
Schwertstrasse 6 Schaffhausen Switzerland
WKN: 888509;ISIN: CH0038389992;Index:HDAX,MIDCAP,TecDAX,TECH All Share,Prime All Share;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse;